Uncategorized
PanOptica Reports Progress with PAN-90806, a Topical Anti-VEGF Eyedrop for the Treatment of Neovascular (Wet) AMD
BERNARDSVILLE, N.J.--(BUSINESS WIRE)--PanOptica briefed investors on the development of PAN-90806, a clinical-stage candidate as a topical anti-vascular endothelial growth factor eyedrop for the treatment of neovascular eye diseases.
